AUPH News and Press, Aurinia Pharmaceuticals Inc From 01/06/23

Aurinia Pharmaceuticals ( NASDAQ: AUPH ) has reported prelim net revenue of ~$28.4M for fourth quarter compared to consensus estimate of $27.13M. For the three months ended Dec. 31, 2022, preliminary unaudited net revenues included net product revenues of ~$28.3M and license a...

Preliminary unaudited net revenue for the fourth quarter and full year 2022 of approximately $28.4 million and $134.0 million Preliminary unaudited net product revenue for the fourth quarter and full year 2022 of approximately $28.3 million and $103.5 million Reiterates net produc...

Summary Aurinia Pharmaceuticals Inc. recently settled a patent dispute with Sun Pharma. That seems to have rekindled buyout chatter. However, without an actual buy - which is an unpredictable event - Aurinia Pharmaceuticals has no upside, given poor voclosporin sales. In m...

Summary Aurinia Pharmaceuticals recently announced they have reached a settlement with Sun Pharmaceuticals concerning the patent challenge for Lupkynis. Both companies will dismiss their claims and counterclaims against each other. Following the settlement announcement, AUPH shares jump...

Aurinia Pharmaceuticals Inc. (NASDAQ: AUPH) (Aurinia or the Company) today announced that Peter Greenleaf, President and Chief Executive Officer, is scheduled to present at the 41 st Annual J.P. Morgan Healthcare Conference on Wednesday, January 11 th at 4:30 p.m. Pacific Time / 7:30 p.m....

Aurinia Pharmaceuticals ( NASDAQ: AUPH ) rose 5% amid speculation the company may be a takeover target after Tuesday's patent settlement with Sun Pharmaceuticals. Aurinia ( AUPH ) surged 38% on Tuesday after the company said it reached a settlement with India's Sun Pharmac...

Canada-based Aurinia Pharmaceuticals ( NASDAQ: AUPH ) on Tuesday said it had reached a settlement with India's Sun Pharmaceuticals ( OTCPK:SMPQY ) over its patent challenge of its lupus nephritis treatment Lupkynis. AUPH shares were 36.1% higher to $5.88 after the opening bell...

- Sun Pharmaceuticals and Aurinia agreed to file a joint motion to dismiss Inter Parties Review of Patent No. 10,286,036 - Parties have settled the patent infringement claim against Sun’s CEQUA® product - Settlements are Contingent Upon U.S. Patent Trial and Appeal Board (PTAB...

MHRA Approval follows European Commission marketing authorization of LUPKYNIS to treat adults with active lupus nephritis in 27 European Union Member States LUPKYNIS is the first oral medicine approved in the U.S. and Europe for the treatment of adults living with active lupus nephritis ...

Summary Aurinia has been facing many problems. Potential sales chatter may be a result of its problems. However, I see little reason for big pharma to buy AUPH. Aurinia’s ( AUPH ) price movement over the last 12 months seems predicated on 3 things - key ma...